Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 388870Orphan Drug1 approvals3 trials

Pharos iBio Co., Ltd.

Official website

Pharos iBio is a KOSDAQ-listed biotech developing drugs for rare, intractable diseases including cancer using its AI platform Chemiverse.

As of 2026-10-08, Pharos iBio Co., Ltd. has 3 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2016 and listed on KOSDAQ in 2023, Pharos iBio is a research and development company focused on innovative therapies for rare and intractable diseases, particularly oncology. Using its AI-driven drug discovery platform Chemiverse, the company has built a pipeline including the acute myeloid leukemia candidate Lasmotinib (PHI-101), the recurrent ovarian cancer candidate PHI-101-OC, the FAK inhibitor PHI-301, and the NRAS AML candidate PHI-501. Pharos iBio manufactures no marketed drug itself, instead pursuing conditional approval after Phase 2 trials and out-licensing of candidates as its business model, and Lasmotinib (PHI-101) received orphan drug designations from the US FDA in 2019, Korea's MFDS in 2024 (the country's 53rd such designation), and the EU EMA in 2025.

Products & technology

  • Lasmotinib (PHI-101)Acute myeloid leukemia (AML) treatment targeting FLT3 mutations
  • PHI-101-OCRecurrent ovarian cancer treatment
  • PHI-301FAK inhibitor-based composition for enhancing radiosensitivity
  • PHI-501NRAS AML treatment, indication expanded to refractory solid tumors

Regulatory approvals

1 Orphan Drug designations · 2024

  • OrphanPHI-101(경구제)2024-09-03
    Orphan Drug designation · in development20240150685

Clinical trials

data.go.kr

3 MFDS clinical trial authorisations · 2020–2025 (Phase 1 3)

  • Phase 1PHI-5012025-06-25

    6 trial sites

  • Phase 1PHI-1012020-11-06

    9 trial sites

  • Phase 1PHI-1012020-02-07

    21 trial sites

R&D and key agreements

Source: DART corporate disclosure

PHI-101(라스모티닙) · 급성골수성백혈병(AML) · 임상 1상 완료, CSR 수령(2025.6.30) · Received orphan drug designations from the US FDA (2019), Korea MFDS (2024, the country's 53rd such designation), and EU EMA (2025); an investigator-initiated trial (IIT) is ongoing for minimal residual disease (MRD)

PHI-101-OC · 재발성 난소암 · 임상 1상 진행 중 · Preclinical evaluation showed efficacy in cell and in vivo models regardless of BRCA mutation status; Phase 1 trial initiated November 2020

PHI-301 · 방사선 민감성 증진(FAK 저해제) · 선도물질 단계 · Under development via an exclusive license from the Korea Institute of Radiological & Medical Sciences

PHI-501 · NRAS AML / 난치성 고형암 · 임상 1상 진행 중 · Patent acquired from the Korea Institute of Science and Technology; indication expanded to refractory solid tumors using the Chemiverse AI platform

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 18 more patents

AI reads

MAA server logs · IP-verified
38
Times AI engines pulled Pharos iBio Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

38
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

6
live 0
Last 7 days
30
live 0
Last 30 days
38
live 0
All time
  • OpenAIOAI-SearchBot31
  • PerplexityPerplexityBot3
  • GoogleGoogleOther2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Pharos iBio Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition